CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million

Reuters03-30

CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million

CF PharmTech posted net income attributable to owners of RMB 2.5 million, down 88.22%.
Revenue fell 29% to RMB 430 million.
Gross margin narrowed 5.1 percentage points to 75.8% on lower CF017 pricing under VBP renewal and a mix shift toward lower-margin CF018.
CF017 revenue dropped to RMB 340 million, while CF018 climbed to RMB 79 million; overseas revenue topped RMB 10 million, with cumulative overseas orders exceeding 16 million units.
Management expects 2026 to be a year of resumed growth as CF017 procurement and execution normalize, supported by channel partnerships spanning primary care and online distribution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12077165), on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623397797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 16:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623397797","market":"fut","top_or_hot":-1,"title":"CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          CF PharmTech posted net income attributable to owners of RMB 2.5 million, down 88.22%.\n        </li>\n<li>\n          Revenue fell 29% to RMB 430 million.\n        </li>\n<li>\n          Gross margin narrowed 5.1 percentage points to 75.8% on lower CF017 pricing under VBP renewal and a mix shift toward lower-margin CF018.\n        </li>\n<li>\n          CF017 revenue dropped to RMB 340 million, while CF018 climbed to RMB 79 million; overseas revenue topped RMB 10 million, with cumulative overseas orders exceeding 16 million units.\n        </li>\n<li>\n          Management expects 2026 to be a year of resumed growth as CF017 procurement and execution normalize, supported by channel partnerships spanning primary care and online distribution.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12077165), on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 16:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          CF PharmTech posted net income attributable to owners of RMB 2.5 million, down 88.22%.\n        </li>\n<li>\n          Revenue fell 29% to RMB 430 million.\n        </li>\n<li>\n          Gross margin narrowed 5.1 percentage points to 75.8% on lower CF017 pricing under VBP renewal and a mix shift toward lower-margin CF018.\n        </li>\n<li>\n          CF017 revenue dropped to RMB 340 million, while CF018 climbed to RMB 79 million; overseas revenue topped RMB 10 million, with cumulative overseas orders exceeding 16 million units.\n        </li>\n<li>\n          Management expects 2026 to be a year of resumed growth as CF017 procurement and execution normalize, supported by channel partnerships spanning primary care and online distribution.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12077165), on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL4wY27L:1","article_id":"2623397797","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623397797","pubTimestamp":1774859529,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CF PharmTech posted net income attributable to owners of RMB 2.5 million, down 88.22%.Gross margin narrowed 5.1 percentage points to 75.8% on lower CF017 pricing under VBP renewal and a mix shift toward lower-margin CF018.CF017 revenue dropped to RMB 340 million, while CF018 climbed to RMB 79 million; overseas revenue topped RMB 10 million, with cumulative overseas orders exceeding 16 million units.Management expects 2026 to be a year of resumed growth as CF017 procurement and execution normalize, supported by channel partnerships spanning primary care and online distribution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业","BK1191":"制药"},"translate_title":"CF Pharmtech 2025财年利润下降88.2%至250万元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":0.9},"content_text":"CF Pharmtech FY25 profit drops 88.2% to RMB 2.5 million\n    \n\n\n          CF PharmTech posted net income attributable to owners of RMB 2.5 million, down 88.22%.\n        \n\n          Revenue fell 29% to RMB 430 million.\n        \n\n          Gross margin narrowed 5.1 percentage points to 75.8% on lower CF017 pricing under VBP renewal and a mix shift toward lower-margin CF018.\n        \n\n          CF017 revenue dropped to RMB 340 million, while CF018 climbed to RMB 79 million; overseas revenue topped RMB 10 million, with cumulative overseas orders exceeding 16 million units.\n        \n\n          Management expects 2026 to be a year of resumed growth as CF017 procurement and execution normalize, supported by channel partnerships spanning primary care and online distribution.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12077165), on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623397797","isCrawlerRequest":true}